Douglass Winthrop Advisors’s GSK GSK Stock Holding History

Douglass Winthrop Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4,288	Closed	-$218K	–	246
2017 Q3	$218K	Sell	4,288 -1,944	-31%	-$98.6K	0.01%	239
2017 Q2	$336K	Buy	6,232 +600	+11%	+$32K	0.02%	193
2017 Q1	$297K	Hold	5,632	–	–	0.02%	203
2016 Q4	$271K	Sell	5,632 -21	-0.4%	-$1.04K	0.02%	203
2016 Q3	$305K	Hold	5,653	–	–	0.02%	191
2016 Q2	$306K	Sell	5,653 -800	-12%	-$42.1K	0.02%	191
2016 Q1	$327K	Sell	6,453 -1,600	-20%	-$79.7K	0.02%	183
2015 Q4	$406K	Sell	8,053 -3,424	-30%	-$175K	0.03%	175
2015 Q3	$552K	Buy	11,477 +920	+9%	+$47.9K	0.04%	148
2015 Q2	$609K	Hold	10,557	–	–	0.05%	157
2015 Q1	$609K	Buy	+10,557	New	+$605K	0.05%	157

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Douglass Winthrop Advisors's GSK Position: Q4 2017 in Review

Douglass Winthrop Advisors sold out of GSK (GSK) in Q4 2017, closing a stake of 4,288 shares — an estimated $218K sold.

Douglass Winthrop Advisors first reported a position in GSK in Q1 2015 and held it in 11 quarters. The position peaked at $609K in Q2 2015. 763 funds tracked by Wall St. Rank hold GSK as of Q4 2017.

Douglass Winthrop Advisors reported no remaining GSK position as of Q4 2017 after selling out during the quarter.
Douglass Winthrop Advisors sold 4,288 GSK shares in Q4 2017, an estimated $218K.
Douglass Winthrop Advisors first reported a position in GSK in Q1 2015 and held it in 11 quarters.
Douglass Winthrop Advisors's GSK position peaked at $609K in Q2 2015.
763 funds tracked by Wall St. Rank held GSK as of Q4 2017.

Based on Douglass Winthrop Advisors's 13F filing for Q4 2017, filed 13 Feb 2018.